Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease
Authors/Creators
Alan Rembach
Noel G. Faux
Andrew D. Watt
Kelly K. Pertile
Rebecca L. Rumble
Brett O. Trounson
Christopher J. Fowler
Blaine R. Roberts
Keyla A. Perez
Qiao-Xin Li
Simon M. Laws, Edith Cowan UniversityFollow
Kevin Taddei, Edith Cowan UniversityFollow
Stephanie Rainey-Smith, Edith Cowan UniversityFollow
Joanne S. Robertson
Manu Vandijck
Hugo Vanderstichele
Kevin J. Barnham
Kathryn A. Ellis
Cassandra Szoeke
Lance MacAulay
Christopher C. Rowe
Victor L. Villemagne
David Ames
Ralph N. Martins, Edith Cowan UniversityFollow
Ashley I. Bush
Colin L. Masters
Abstract
Background: A practical biomarker is required to facilitate the preclinical diagnosis of Alzheimer's disease (AD). Methods: Plasma amyloid beta (Aβ)1-40, Aβ1-42, Aβn-40, and Aβn-42 peptides were measured at baseline and after 18 months in 771 participants from the Australian Imaging Biomarkers and Lifestyle (AIBL) study of aging. Aβ peptide levels were compared with clinical pathology, neuroimaging and neuropsychological measurements. Results: Although inflammatory and renal function covariates influenced plasma Aβ levels significantly, a decrease in Aβ1-42/Aβ1-40 was observed in patients with AD, and was also inversely correlated with neocortical amyloid burden. During the 18 months, plasma Aβ1-42 decreased in subjects with mild cognitive impairment (MCI) and in those transitioning from healthy to MCI. Conclusion: Our findings are consistent with a number of published plasma Aβ studies and, although the prognostic value of individual measures in any given subject is limited, the diagnostic contribution of plasma Aβ may demonstrate utility when combined with a panel of peripheral biomarkers.
Keywords
Alzheimer's disease, Amyloid-β, Biomarkers, Diagnosis, Pittsburgh compound B, Positron emission tomography, amyloid beta protein, amyloid beta protein[1-40], amyloid beta protein[1-42], amyloid beta protein[n-40], amyloid beta protein[n-42], Pittsburgh compound B, unclassified drug, aged, aging, Alzheimer disease, article, cohort analysis, enzyme linked immunosorbent assay, episodic memory, executive function, female, follow up, human, kidney function, Kruskal Wallis test, lifestyle, longitudinal study, major clinical study, male, mild cognitive impairment, neuroimaging, neuropsychology, pathology, positron emission tomography, priority journal, Alzheimer's disease, Amyloid-β, Biomarkers, Diagnosis, Pittsburgh compound B, Positron emission tomography, Aged, Aged, 80 and over, Aging, Alzheimer Disease, Amyloid beta-Peptides, Apolipoprotein E4, Chi-Square Distribution, Cohort Studies, Disease Progression, Female, Humans, Male, Middle Aged, Mild Cognitive Impairment, Neuropsychological Tests, Peptide Fragments, Positron-Emission Tomography
Document Type
Journal Article
Date of Publication
1-1-2014
Faculty
Faculty of Health, Engineering and Science
Publisher
Elsevier
School
School of Medical Sciences
RAS ID
18787
Copyright
subscription content
Comments
Rembach A., Faux N.G., Watt A.D., Pertile K.K., Rumble R.L., Trounson B.O., Fowler C.J., Roberts B.R., Perez K.A., Li Q.-X., Laws S.M., Taddei K., Rainey-Smith S., Robertson J.S., Vandijck M., Vanderstichele H., Barnham K.J., Ellis K.A., Szoeke C., MacAulay L., Rowe C.C., Villemagne V.L., Ames D., Martins R.N., Bush A.I., Masters C.L. (2014). Changes in plasma amyloid beta in a longitudinal study of aging and Alzheimer's disease. Alzheimer's and Dementia, 10(1), 53-61. Available here